Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
Clinical trial NCT02286817 · COMPLETED
Trial details
- NCT number
- NCT02286817
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-01-01
- Primary completion
- 2015-05-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.